Search by Drug Name or NDC
NDC 00074-3956-46 Kaletra 80; 20 mg/mL; mg/mL Details
Kaletra 80; 20 mg/mL; mg/mL
Kaletra is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is LOPINAVIR; RITONAVIR.
MedlinePlus Drug Summary
The combination of lopinavir and ritonavir is used with other medications to treat human immunodeficiency virus (HIV) infection. Lopinavir and ritonavir are in a class of medications called protease inhibitors. They work by decreasing the amount of HIV in the blood. When lopinavir and ritonavir are taken together, ritonavir also helps to increase the amount of lopinavir in the body so that the medication will have a greater effect. Although lopinavir and ritonavir will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 00074-3956-46Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Lopinavir and Ritonavir
Product Information
| NDC | 00074-3956 |
|---|---|
| Product ID | 0074-3956_d38d7a08-7c06-4262-961d-00e54cf20378 |
| Associated GPIs | 12109902552020 |
| GCN Sequence Number | 046601 |
| GCN Sequence Number Description | lopinavir/ritonavir SOLUTION 400-100/5 ORAL |
| HIC3 | W5M |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITOR COMB |
| GCN | 31782 |
| HICL Sequence Number | 021582 |
| HICL Sequence Number Description | LOPINAVIR/RITONAVIR |
| Brand/Generic | Brand |
| Proprietary Name | Kaletra |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Lopinavir and Ritonavir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 80; 20 |
| Active Ingredient Units | mg/mL; mg/mL |
| Substance Name | LOPINAVIR; RITONAVIR |
| Labeler Name | AbbVie Inc. |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A In |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA021251 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00074-3956-46 (00074395646)
| NDC Package Code | 0074-3956-46 |
|---|---|
| Billing NDC | 00074395646 |
| Package | 1 BOTTLE in 1 CARTON (0074-3956-46) / 160 mL in 1 BOTTLE |
| Marketing Start Date | 2010-06-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |